Results 31 to 40 of about 22,921 (208)

Development of a Supercritical Fluid Chromatography-Tandem Mass Spectrometry Method for the Determination of Azacitidine in Rat Plasma and Its Application to a Bioavailability Study

Molecules, 2013
Azacitidine is widely used for the treatment of myelodysplastic syndromes (MDS) and acute myelogenous leukaemia (AML). The analysis of azacitidine in biological samples is subject to interference by endogenous compounds.
Dongpo Li, Tianhong Zhang, Longfa Kou, Youxi Zhang, Jin Sun, Zhonggui He   +5 more
doaj   +1 more source

Effectiveness of azacitidine for the treatment of higher-risk myelodysplastic syndromes in daily practice: the authors' reply [PDF]

, 2016
There is an increasing interest on the effectiveness of azacitidine for the treatment of higher-risk myelodysplastic syndromes (MDS) outside clinical trials. We recently reported the lack of effect of this drug in an unselected population of 821 patients.
Bernal del Castillo, Teresa, Martínez Camblor, Pablo, Sanz, Guillermo, Sánchez García, Joaquín   +3 more
core   +1 more source

Randomized study of continuous high-dose lenalidomide, sequential azacitidine and lenalidomide, or azacitidine in persons 65 years and over with newly-diagnosed acute myeloid leukemia

Haematologica, 2018
Therapy of acute myeloid leukemia in older persons is associated with poor outcomes because of intolerance to intensive therapy, resistant disease and co-morbidities.
Bruno C. Medeiros, Kelly McCaul, Suman Kambhampati, Daniel A. Pollyea, Rajat Kumar, Lewis R. Silverman, Andrea Kew, Lalit Saini, CL Beach, Ravi Vij, Xiwei Wang, Jim Zhong, Robert Peter Gale   +12 more
doaj   +1 more source

The combination of FLT3 and DNA methyltransferase inhibition is synergistically cytotoxic to FLT3/ITD acute myeloid leukemia cells [PDF]

, 2015
Effective treatment regimens for elderly acute myeloid leukemia (AML) patients harboring internal tandem duplication mutations in the FMS-like tyrosine kinase-3 (FLT3) gene (FLT3/ITD) are lacking and represent a significant unmet need. Recent data on the
Chang, Emily, Ganguly, Sudipto, Gocke, Christopher D., Konig, Heiko, Levis, Mark, Rajkhowa, Trivikram   +5 more
core   +1 more source

In vitro effect of eltrombopag alone and in combination with azacitidine on megakaryopoiesis in patients with myelodysplastic syndrome

Platelets, 2021
Thrombocytopenia is a severe complication for patients with myelodysplastic syndrome (MDS). Eltrombopag increases platelet count in MDS patients but its combination with azacitidine elicited controversial results.
Francesco D’Alò, Ilaria Zangrilli, Elisa Cupelli, Luana Fianchi, Marianna Criscuolo, Giulia Falconi, Emiliano Fabiani, Livio Pagano, Stefan Hohaus, Valerio De Stefano   +9 more
doaj   +1 more source

Response to treatment with azacitidine in children with advanced myelodysplastic syndrome prior to hematopoietic stem cell transplantation

Haematologica, 2016
Advanced myelodysplastic syndrome harbors a high risk of progression to acute myeloid leukemia and poor prognosis. In children, there is no established treatment to prevent or delay progression to leukemia prior to hematopoietic stem cell transplantation.
Nicolas Waespe, Machiel Van Den Akker, Robert J. Klaassen, Lani Lieberman, Meredith S. Irwin, Salah S. Ali, Mohamed Abdelhaleem, Bozana Zlateska, Mira Liebman, Michaela Cada, Tal Schechter, Yigal Dror   +11 more
doaj   +1 more source

Enasidenib in the treatment of relapsed/refractory acute myeloid leukemia: an evidence-based review of its place in therapy. [PDF]

, 2019
Introduction: Acute myeloid leukemia (AML) remains a disease with high mortality, especially for older patients and those with relapsed/refractory (R/R) disease.
Galkin, Maria, Jonas, Brian A
core   +1 more source

Metastasis on pause: How dormant tumor cells stay hidden within the tumor microenvironment and evade immune surveillance

Molecular Oncology, EarlyView.
Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary, Jose Javier Bravo‐Cordero   +1 more
wiley   +1 more source

Real‐world study of the use of azacitidine in myelodysplasia in Australia

eJHaem
Hypomethylating agents are the most widely used upfront therapy for patients with myelodysplastic syndrome (MDS) who are not suitable for hematopoietic stem cell transplantation.
Anoop Enjeti, Asma Ashraf, Vincent Caillet, Arif Alam, Jonathan Silar, Harold Keer, Francesco Castaldi, Taleisha Paine   +7 more
doaj   +1 more source

Cost-effectiveness of azacitidine compared with low-doses of chemotherapy (LDC) in myelodysplastic syndrome (MDS)

Global & Regional Health Technology Assessment, 2017
IntroductionMyelodysplastic syndrome (MDS) comprises a group of clonal hematological disorders, characterized by ineffective hematopoiesis and progressive bone marrow failure.
Myrna Candelaria-Hernández, Xavier López Karpovitch, Francisco Javier Mijangos, Efreen Montaño, Arely Lemus Carmona, Silvia Guzmán Vázquez, Herman Soto Molina   +6 more
doaj   +1 more source